Design, Synthesis, and Evaluation of Homochiral Peptides Containing Arginine and Histidine As Molecular Transporters

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2018 Jul 4

PMID 29966296

Citations 12

Authors

Naglaa Salem El-Sayed

Taryn Miyake

Amir N Shirazi

Shang Eun Park

Jimmy Clark

Stephani Buchholz

Keykavous Parang

Rakesh Tiwari

Affiliations

Soon will be listed here.

Abstract

Linear (HR) and cyclic [HR] peptides (n = 4,5) containing alternate arginine and histidine residues were synthesized. The peptides showed 0⁻15% cytotoxicity at 5⁻100 µM in human ovarian adenocarcinoma (SK-OV-3) cells while they exhibited 0⁻12% toxicity in human leukemia cancer cell line (CCRF-CEM). Among all peptides, cyclic [HR]₄ peptide was able to improve the delivery of a cell impermeable fluorescence-labeled phosphopeptide by two-fold. Fatty acids of different alkyl chain length were attached at the -terminal of the linear peptide (HR)₄ to improve the molecular transporter property. Addition of fatty acyl chains was expected to help with the permeation of the peptides through the cell membrane. Thus, we synthesized seven fatty acyl derivatives of the linear (HR)₄ peptide. The peptides were synthesized using Fmoc/Bu solid phase peptide chemistry, purified by reverse-phase high-performance liquid chromatography (RP-HPLC) and characterized by matrix-assisted laser desorption/ionization (MALDI) spectrometry. The fatty acyl peptides containing C₈, C, C, and C alkyl chain did not show cytotoxicity on SK-OV-3 or CCRF-CEM cell lines up to 50 µM concentration; however, at higher concentration (100 µM), they showed mild cytotoxicity. For example, C-(HR)₄ was also found to reduce the proliferation of SK-OV-3 cells by 11% at 50 µM and C-(HR)₄ showed mild toxicity at 10 µM, reducing the proliferation of SK-OV-3 cells by 21%. Increase in the length of alkyl chain showed cytotoxicity to the cell lines. C-(HR)₄ peptide showed better efficiency in translocation of F′-GpYEEI to SK-OV-3 than the phosphopeptide alone. Further investigation of C-(HR)₄ peptide efficacy showed that the peptide could deliver doxorubicin and epirubicin into SK-OV-3 and also improved the drug antiproliferative ability. These studies provided insights into understanding the structural requirements for optimal cellular delivery of the fatty acyl-(HR)₄ peptide conjugates.

Citing Articles

Intracellular Protein Delivery: Approaches, Challenges, and Clinical Applications.

Chan A, Tsourkas A BME Front. 2024; 5:0035.

PMID: 38282957 PMC: 10809898. DOI: 10.34133/bmef.0035.

Intracellular Delivery of Stabilized Peptide Blocking MTDH-SND1 Interaction for Breast Cancer Suppression.

Chen H, Zhan M, Zhang Y, Liu J, Wang R, An Y JACS Au. 2024; 4(1):139-149.

PMID: 38274259 PMC: 10806767. DOI: 10.1021/jacsau.3c00573.

Ionizable drug delivery systems for efficient and selective gene therapy.

Zhang Y, Guo R, Chen Y, Li T, Du W, Xiang R Mil Med Res. 2023; 10(1):9.

PMID: 36843103 PMC: 9968649. DOI: 10.1186/s40779-023-00445-z.

Oleyl Conjugated Histidine-Arginine Cell-Penetrating Peptides as Promising Agents for siRNA Delivery.

Sajid M, Mandal D, El-Sayed N, Lohan S, Moreno J, Tiwari R Pharmaceutics. 2022; 14(4).

PMID: 35456715 PMC: 9028392. DOI: 10.3390/pharmaceutics14040881.

How Cargo Identity Alters the Uptake of Cell-Penetrating Peptide (CPP)/Cargo Complexes: A Study on the Effect of Net Cargo Charge and Length.

Hymel H, Rahnama A, Sanchez O, Liu D, Gauthier T, Melvin A Cells. 2022; 11(7).

PMID: 35406759 PMC: 8997848. DOI: 10.3390/cells11071195.

References

Liu B, Huang Y, Winiarz J, Chiang H, Lee H . Intracellular delivery of quantum dots mediated by a histidine- and arginine-rich HR9 cell-penetrating peptide through the direct membrane translocation mechanism. Biomaterials. 2011; 32(13):3520-37. DOI: 10.1016/j.biomaterials.2011.01.041. View

Olson E, Jiang T, Aguilera T, Nguyen Q, Ellies L, Scadeng M . Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc Natl Acad Sci U S A. 2010; 107(9):4311-6. PMC: 2840175. DOI: 10.1073/pnas.0910283107. View

Madani F, Abdo R, Lindberg S, Hirose H, Futaki S, Langel U . Modeling the endosomal escape of cell-penetrating peptides using a transmembrane pH gradient. Biochim Biophys Acta. 2012; 1828(4):1198-204. DOI: 10.1016/j.bbamem.2012.12.008. View

Wagstaff K, Jans D . Protein transduction: cell penetrating peptides and their therapeutic applications. Curr Med Chem. 2006; 13(12):1371-87. DOI: 10.2174/092986706776872871. View

Nasrolahi Shirazi A, Tiwari R, Oh D, Banerjee A, Yadav A, Parang K . Efficient delivery of cell impermeable phosphopeptides by a cyclic peptide amphiphile containing tryptophan and arginine. Mol Pharm. 2013; 10(5):2008-20. PMC: 3653137. DOI: 10.1021/mp400046u. View

Zorko M, Langel U . Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Adv Drug Deliv Rev. 2005; 57(4):529-45. DOI: 10.1016/j.addr.2004.10.010. View

Nasrolahi Shirazi A, Tiwari R, Chhikara B, Mandal D, Parang K . Design and biological evaluation of cell-penetrating peptide-doxorubicin conjugates as prodrugs. Mol Pharm. 2013; 10(2):488-99. DOI: 10.1021/mp3004034. View

Nasrolahi Shirazi A, Paquin K, Howlett N, Mandal D, Parang K . Cyclic peptide-capped gold nanoparticles for enhanced siRNA delivery. Molecules. 2014; 19(9):13319-31. PMC: 6271229. DOI: 10.3390/molecules190913319. View

Reissmann S . Cell penetration: scope and limitations by the application of cell-penetrating peptides. J Pept Sci. 2014; 20(10):760-84. DOI: 10.1002/psc.2672. View

10.

Stewart K, Horton K, Kelley S . Cell-penetrating peptides as delivery vehicles for biology and medicine. Org Biomol Chem. 2008; 6(13):2242-55. DOI: 10.1039/b719950c. View

11.

Deshayes S, Morris M, Divita G, Heitz F . Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell Mol Life Sci. 2005; 62(16):1839-49. PMC: 11139131. DOI: 10.1007/s00018-005-5109-0. View

12.

Murphy E, Majeti B, Barnes L, Makale M, Weis S, Lutu-Fuga K . Nanoparticle-mediated drug delivery to tumor vasculature suppresses metastasis. Proc Natl Acad Sci U S A. 2008; 105(27):9343-8. PMC: 2453735. DOI: 10.1073/pnas.0803728105. View

13.

Semenza G . Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 2009; 29(5):625-34. PMC: 2969168. DOI: 10.1038/onc.2009.441. View

14.

Mae M, El Andaloussi S, Lundin P, Oskolkov N, Johansson H, Guterstam P . A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy. J Control Release. 2008; 134(3):221-7. DOI: 10.1016/j.jconrel.2008.11.025. View

15.

Nasrolahi Shirazi A, El-Sayed N, Mandal D, Tiwari R, Tavakoli K, Etesham M . Cysteine and arginine-rich peptides as molecular carriers. Bioorg Med Chem Lett. 2015; 26(2):656-661. DOI: 10.1016/j.bmcl.2015.11.052. View

16.

Katayama S, Hirose H, Takayama K, Nakase I, Futaki S . Acylation of octaarginine: Implication to the use of intracellular delivery vectors. J Control Release. 2010; 149(1):29-35. DOI: 10.1016/j.jconrel.2010.02.004. View

17.

Mae M, Langel U . Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery. Curr Opin Pharmacol. 2006; 6(5):509-14. DOI: 10.1016/j.coph.2006.04.004. View

18.

Mandal D, Nasrolahi Shirazi A, Parang K . Self-assembly of peptides to nanostructures. Org Biomol Chem. 2014; 12(22):3544-61. PMC: 4038164. DOI: 10.1039/c4ob00447g. View

19.

Bacalum M, Janosi L, Zorila F, Tepes A, Ionescu C, Bogdan E . Modulating short tryptophan- and arginine-rich peptides activity by substitution with histidine. Biochim Biophys Acta Gen Subj. 2017; 1861(7):1844-1854. DOI: 10.1016/j.bbagen.2017.03.024. View

20.

Lee E, Shin H, Na K, Bae Y . Poly(L-histidine)-PEG block copolymer micelles and pH-induced destabilization. J Control Release. 2003; 90(3):363-74. DOI: 10.1016/s0168-3659(03)00205-0. View